Sign up to save your podcasts
Or
Share PCSK9 Inhibitors: Is There a Palatable Price Point?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
PCSK9 Inhibitors: Is There a Palatable Price Point?
The American Heart Association sessions featured two new analyses from the FOURIER trial, which prompted a discussion on the cost-effectiveness of PCSK9 inhibitor lipid-lowering therapy.
View all episodes
By MedscapeThe American Heart Association sessions featured two new analyses from the FOURIER trial, which prompted a discussion on the cost-effectiveness of PCSK9 inhibitor lipid-lowering therapy.